Table 2 –

Covariate-adjusted estimates of efficacy and toxicity across salvage modalities

	2-yr RFS (95% CI)	5-yr RFS (95% CI)	Severe GU toxicity (95% CI)	Severe GI toxicity (95% CI)
RP	69 (64–74)	54 (49–59)	21 (16–27)	1.9 (0.6–3.7)
Number of studies	26	21	43	43
Number of patients	1439	1488	1617	1617
Heterogeneity (95% PI)	48–84	34–73	0.1–58	0.0–13
Cryotherapy	68 (62–73)	50 (44–56)	15 (10–22)	1.7 (1.0–2.7)
Number of studies	24	18	23	22
Number of patients	3887	3616	2618	2475
Heterogeneity (95% PI)	40–87	28–73	0.0–48	0.2–4.1
HIFU	54 (48–60)	53 (43–63)	23 (17–29)	1.6 (0.9–2.4)
Number of studies	14	7	19	19
Number of patients	1092	236	1737	1737
Heterogeneity (95% PI)	36–71	34–71	4.2–49	0.9–2.4
SBRT	62 (47–74)	60 (N/A)	4.2 (0.8–9.1)	0.0 (0.0–0.1)
Number of studies	5	1	8	8
Number of patients	206	50	261	261
Heterogeneity (95% PI)	49–73	NA	0.0–15	0.0–0.1
HDR	77 (70–83)	60 (52–67)	8.0 (5.1–11)	0.0 (0.0–0.2)
Number of studies	14	7	16	15
Number of patients	456	350	586	571
Heterogeneity (95% PI)	55–90	45–73	2.3–16	0.0–0.2
LDR	81 (74–86)	56 (48–63)	8.1 (4.3–13)	1.5 (0.2–3.4)
Number of studies	22	16	26	26
Number of patients	495	511	664	660
Heterogeneity (95% PI)	57–93	33–76	0.0–31	0.0–5.7

CI = confidence interval; GI = gastrointestinal; GU = genitourinary; HDR = high-dose-rate brachytherapy; HIFU = high-intensity focused ultrasound; LDR = low-dose-rate brachytherapy; NA = not available; PI = prediction interval; RFS = recurrence-free survival; RP = radical prostatectomy; SBRT = stereotactic body radiotherapy.